查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1447590

肝病診斷市場規模- 按疾病類型（肝炎、肝硬化、肝癌、非酒精性脂肪肝病(NAFLD)）、技術（影像、肝臟活體組織切片、內視鏡檢查、實驗室測試）、最終用途- 全球預測（2024 年 -第2032章

Liver Disease Diagnostics Market Size - By Disease Type (Hepatitis, Cirrhosis, Liver Cancer, Non-Alcoholic Fatty Liver Disease (NAFLD)), Technique (Imaging, Liver Biopsy, Endoscopy, Lab Test), End-use - Global Forecast (2024 - 2032)
出版日期: | 出版商: Global Market Insights Inc. | 英文 110 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

在技​​術進步、肝病盛行率上升以及早期診斷意識提高的推動下，全球肝病診斷市場預計在 2024 年至 2032 年期間CAGR為 7.3%。

據世界衛生組織稱，全球有 3.54 億人受到B型或丙型肝炎感染。久坐的生活方式、不健康的飲食習慣和飲酒盛行等因素導致肝臟疾病的增加，從而增加了對先進診斷解決方案的需求。此外，人口老化，特別是在已開發地區，更容易患肝臟相關疾病。此外，強調早期發現和介入以預防嚴重併發症正在促進肝病診斷測試和程序的採用。

整個肝病診斷行業根據疾病類型、技術、最終用途和地區進行分類。

由於死亡率高和治療選擇有限，特別是在晚期，肝癌細分市場預計到 2032 年將大幅成長。因此，迫切需要準確、及時地診斷肝癌。有多種診斷方式，例如影像技術（CT 掃描、MRI）、血液檢查（AFP、AFP-L3）和活體組織切片程序。影像技術和生物標記識別的不斷進步也提高了肝癌診斷的精確度和可靠性，進一步推動了產業的成長。

內視鏡技術領域預計到 2032 年將迅速擴展，提供直接視覺化和組織採樣功能。內視鏡成像技術的發展，包括高清示波器和先進的成像模式，如窄帶成像(NBI) 和共焦雷射內視鏡(CLE)，透過提供對組織形態和血管分佈的詳細了解，正在徹底改變肝臟疾病的診斷，推動細分市場的發展與成長。

由於肝病的高盛行率、完善的醫療基礎設施以及旨在降低肝臟相關發病率和死亡率的積極政府舉措等因素，歐洲肝病診斷市場在預測期內將擁有利潤豐厚的機會。專注於肝臟健康的主要參與者和研究機構的存在進一步增強了該地區的成長前景。此外，老年人口的增加以及對早期診斷重要性的認知不斷提高，正在推動整個歐洲對肝病診斷測試和程序的需求。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 肝臟疾病盛行率增加
      • 吸煙、酗酒和吸毒的人數增加
      • 診斷試劑盒的技術進步
    • 產業陷阱與挑戰
      • 診斷測試成本高
  • 成長潛力分析
  • 監管環境
  • 報銷場景
  • 未來市場趨勢
  • 技術景觀
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司矩陣分析
  • 公司市佔率分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按疾病類型，2018 - 2032

  • 主要趨勢
  • 肝炎
  • 肝硬化
  • 肝癌
  • 非酒精性脂肪肝（NAFLD）
  • 其他疾病類型

第 6 章：市場估計與預測：按技術分類，2018 年 - 2032 年

  • 主要趨勢
  • 影像學
  • 肝臟活體組織切片
  • 內視鏡檢查
  • 實驗室測試

第 7 章：市場估計與預測：按最終用途，2018 - 2032 年

  • 主要趨勢
  • 醫院
  • 實驗室
  • 其他最終用戶

第 8 章：市場估計與預測：按地區分類，2018 年 - 2032 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區

第 9 章：公司簡介

  • Abbott Laboratories
  • BioMerieux SA
  • Bio-Rad Laboratories Inc.
  • Cosara Diagnostics Pvt Ltd.
  • F. Hoffmann-La Roche Ltd.
  • HORIBA Medical
  • Laboratory Corporation of America Holdings
  • Meril Life Sciences Pvt. Ltd.
  • Qiagen N.V.
  • Siemens Healthcare GmbH
  • Thermo Fisher Scientific Inc.
簡介目錄
Product Code: 7939

Global Liver Disease Diagnostics Market is expected to register a CAGR of 7.3% between 2024-2032, fueled by technological advancements, rising prevalence of liver diseases, and increasing awareness about early diagnosis.

According to WHO, globally, 354 million individuals are affected by hepatitis B or C infections. Factors such as sedentary lifestyles, unhealthy dietary habits, and the prevalence of alcohol consumption are contributing to the rise in liver diseases, thereby increasing the demand for advanced diagnostic solutions. Moreover, the aging population, particularly in developed regions, is more susceptible to liver-related ailments. Additionally, the emphasis on early detection and intervention to prevent severe complications is fostering the adoption of liver disease diagnostic tests and procedures.

The overall liver disease diagnostics industry is classified based on disease type, technique, end-use, and region.

The liver cancer segment is poised to grow substantially till 2032, owing to the high mortality rate and limited treatment options, especially in advanced stages. Consequently, there is a pressing need for accurate and timely diagnosis of liver cancer. There are various diagnostic modalities such as imaging techniques (CT scan, MRI), blood tests (AFP, AFP-L3), and biopsy procedures. Continuous advancements in imaging technologies and biomarker identification are also enhancing the precision and reliability of liver cancer diagnosis, further propelling industry growth.

The endoscopy technique segment is anticipated to expand rapidly through 2032, offering direct visualization and tissue sampling capabilities. The evolution of endoscopic imaging technologies, including high-definition scopes and advanced imaging modalities such as narrow-band imaging (NBI) and confocal laser endomicroscopy (CLE), is revolutionizing liver disease diagnosis by providing detailed insights into tissue morphology and vascularity, propelling segment growth.

Europe liver disease diagnostics market will have lucrative opportunities during the forecast period, owing to factors such as the high prevalence of liver diseases, well-established healthcare infrastructure, and proactive government initiatives aimed at combating liver-related morbidity and mortality. The presence of key players and research institutions focused on liver health further augments the growth prospects in the region. Additionally, the rising geriatric population and increasing awareness about the importance of early diagnosis are driving the demand for liver disease diagnostic tests and procedures across Europe.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Base estimates & calculations
  • 1.3 Data collection
  • 1.4 Forecast calculations
  • 1.5 Data validation
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increase in prevalence of liver diseases
      • 3.2.1.2 Rise in smoking, alcohol and drug consumption
      • 3.2.1.3 Technological advancements in diagnostic kits
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of diagnostic tests
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Reimbursemnt scenario
  • 3.6 Future market trends
  • 3.7 Technological landscape
  • 3.8 Porter's analysis
    • 3.8.1 Supplier power
    • 3.8.2 Buyer power
    • 3.8.3 Threat of new entrants
    • 3.8.4 Threat of substitutes
    • 3.8.5 Industry rivalry
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Disease Type, 2018 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Hepatitis
  • 5.3 Cirrhosis
  • 5.4 Liver cancer
  • 5.5 Non-alcoholic fatty liver disease (NAFLD)
  • 5.6 Other disease types

Chapter 6 Market Estimates and Forecast, By Technique, 2018 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Imaging
  • 6.3 Liver biopsy
  • 6.4 Endoscopy
  • 6.5 Laboratory tests

Chapter 7 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Laboratories
  • 7.4 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Italy
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
    • 8.5.4 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 South Africa
    • 8.6.3 UAE
    • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

  • 9.1 Abbott Laboratories
  • 9.2 BioMerieux SA
  • 9.3 Bio-Rad Laboratories Inc.
  • 9.4 Cosara Diagnostics Pvt Ltd.
  • 9.5 F. Hoffmann-La Roche Ltd.
  • 9.6 HORIBA Medical
  • 9.7 Laboratory Corporation of America Holdings
  • 9.8 Meril Life Sciences Pvt. Ltd.
  • 9.9 Qiagen N.V.
  • 9.10 Siemens Healthcare GmbH
  • 9.11 Thermo Fisher Scientific Inc.